EPREX STERILE SOLUTION 20000 UNIT / 0.5 ML
EPOETIN ALFA : 20000 UNIT / 0.5 ML · DIN 02243239 · JANSSEN INC
Health Canada status: MARKETED
What is EPREX STERILE SOLUTION?
EPREX STERILE SOLUTION 20000 UNIT / 0.5 ML contains EPOETIN ALFA : 20000 UNIT / 0.5 ML. It is listed in the Health Canada Drug Product Database under DIN 02243239, held by JANSSEN INC, supplied as SOLUTION for INTRAVENOUS ; SUBCUTANEOUS administration. Health Canada currently lists it as marketed, status dated 24-Aug-2005. Nexara Health is a licensed Canadian wholesale distributor (DEL 3-002896-A) and can source this product for hospitals, pharmacies and clinics. Availability and lead time are confirmed per order.
What is EPREX STERILE SOLUTION used for?
Treatment of anemia associated with chronic renal failure, zidovudine-treated HIV, and non-myeloid malignancies receiving chemotherapy. Also used to reduce allogeneic blood transfusions in surgery.
Authorized indication as written in the Health Canada product monograph. For healthcare professionals and licensed purchasers; this is not medical advice.
Product details and regulatory record
| DIN | 02243239 |
|---|---|
| Brand name | EPREX STERILE SOLUTION |
| Generic / active ingredient | EPOETIN ALFA : 20000 UNIT / 0.5 ML |
| Manufacturer | JANSSEN INC |
| Strength | 20000 UNIT / 0.5 ML |
| Dosage form | SOLUTION |
| Route of administration | INTRAVENOUS ; SUBCUTANEOUS |
| Schedule | Prescription |
| ATC code | B03XA01 ERYTHROPOIETIN |
| Biosimilar | No |
| Health Canada status | MARKETED |
| Status date | 24-Aug-2005 |
How is it administered?
Individualize dose to maintain Hb 100-115 g/L (max 120 g/L). CRF: 50-100 IU/kg TIW. Cancer: 150 IU/kg TIW or 40,000 IU QW. Surgery: 600 IU/kg weekly for 3 weeks before surgery.
Included because it drives pack selection and wastage. Consult the monograph.
How is it stored and handled?
Not explicitly detailed in provided text snippet (standard is usually 2-8°C, do not freeze/shake).
How is it supplied?
Single-use pre-filled syringes with PROTECS needle guard and peelable label for tracking.
Contraindications
Pure red cell aplasia (PRCA) after any ESA; uncontrolled hypertension; hypersensitivity to mammalian cell-derived products; patients unable to receive antithrombotic treatment.
Warnings and precautions
Increased risk of death, serious cardiovascular events, and stroke. Risk of tumor progression in cancer patients. Pure red cell aplasia (PRCA) reported. Use caution with history of seizures.
What can be used instead?
Other Canadian products sharing ATC code B03XA01 ERYTHROPOIETIN. 11 of 15 DINs in this group are currently marketed — marketed products are listed first, because that is what can actually be bought. These tables describe supply, not clinical equivalence: substitution rests with the prescriber or pharmacist, and interchangeability is determined provincially.
| Product | Strength | Form | Manufacturer | Health Canada status | DIN |
|---|---|---|---|---|---|
| EPREX STERILE SOLUTION | 30000 UNIT / 0.75 ML | SOLUTION | JANSSEN INC | MARKETED | DIN 02288680 |
| EPREX STERILE SOLUTION 10000IU/1.0ML | 10000 UNIT | SOLUTION | JANSSEN INC | MARKETED | DIN 02231587 |
| EPREX STERILE SOLUTION 1000IU/0.5ML | 1000 UNIT / 0.5 ML | SOLUTION | JANSSEN INC | MARKETED | DIN 02231583 |
| EPREX STERILE SOLUTION 2000IU/0.5ML | 2000 UNIT / 0.5 ML | SOLUTION | JANSSEN INC | MARKETED | DIN 02231584 |
| EPREX STERILE SOLUTION 3000IU/0.3ML | 3000 UNIT / 0.3 ML | SOLUTION | JANSSEN INC | MARKETED | DIN 02231585 |
| EPREX STERILE SOLUTION 40000IU/ML | 40000 UNIT | SOLUTION | JANSSEN INC | MARKETED | DIN 02240722 |
| EPREX STERILE SOLUTION 4000IU/0.4ML | 4000 UNIT / 0.4 ML | SOLUTION | JANSSEN INC | MARKETED | DIN 02231586 |
| EPREX STERILE SOLUTION 5000IU/0.5ML | 5000 UNIT / 0.5 ML | SOLUTION | JANSSEN INC | MARKETED | DIN 02243400 |
| EPREX STERILE SOLUTION 6000 IU/0.6 ML | 6000 UNIT / 0.6 ML | SOLUTION | JANSSEN INC | MARKETED | DIN 02243401 |
| EPREX STERILE SOLUTION 8000 IU/0.8 ML | 8000 UNIT / 0.8 ML | SOLUTION | JANSSEN INC | MARKETED | DIN 02243403 |
Who else supplies ERYTHROPOIETIN worldwide?
Nexara tracks national medicine registries and published price lists across multiple markets. ERYTHROPOIETIN appears in 41 registered pack listings across 3 markets, published on 3 different national price bases. Where a Canadian route is closed, that is where an alternative route of supply starts — subject to the import rules in both countries.
Registered listings are not stock. Ask us to confirm what can actually be sourced for your order.
How can I get it?
Nexara Health supplies this product to licensed Canadian buyers — pharmacies, hospitals, clinics, licensed distributors, and clinical trial sponsors or their CROs. We confirm stock, pack size, expiry and pricing at the time of quotation. If the product is on backorder or in shortage, we identify equivalent alternatives and import options where permitted.
Ordering questions
Who can buy this from Nexara?
Licensed entities only. Nexara holds Health Canada establishment licence DEL 3-002896-A and ships only to a licensed address.
Is there a minimum order?
Yes, set per product line and per pack multiple rather than on the order total, so you are never asked to buy a part-pack. The minimum for this line is confirmed with your quote.
What is the lead time?
Confirmed per order at quotation, and it depends on current stock position and whether the product is in shortage.
Can Nexara supply this for a clinical trial?
Yes — comparator and background-therapy supply, including sourcing from other markets where a Canadian pack will not satisfy the protocol. Clinical trial supply.